About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3035835
Allelic
Composition
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (9 available); any Kras mutation (76 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• survival for around 35 days after pI-pC treatment
• survival of around 58 days even without pI-pC treatment

neoplasm
• 7 of 25 mice injected with pIpC develop thymic T cell lymphoblastic lymphomas
• 2 of 6 non pIpC treated mice show thymic lymphomas
• 10 of 17 mice injected with pIpC exhibit multiple nodules in the lungs consisting of proliferating type II penumocytes
• 5 of 6 non pIpC treated mice show pulmonary adenomas
• squamous papillomas
• 8 of 22 mice injected with pIpC develop squamous papillomas involving the esophageal mucosa
• 8 of 25 mice injected with pIpC develop squamous papillomas involving the oral mucosa
• 2 of 6 non-pIpC treated mice show oral squamous papillomas
• 12 of 19 mice injected with pIpC develop squamous papillomas involving the anal and vulvo-vaginal skin and 8 of 22 mice develop squamous papillomas involving the ear
• 2 of 6 non-pIpC treated mice show ear squamous papillomas

growth/size/body
• becoming emaciated
• mice injected with pIpC develop moderate to severe splenomegaly

hematopoietic system
• mice injected with pIpC develop moderate to severe splenomegaly
• develop lethal hematopoietic disease
• 4-7 week old mice injected with pIpC develop a myeloproliferative disorder
• bone marrow of mice injected with pIpC shows myelomonocytic expansion
• all mice that are not treated with pIpC also develop a hematopoietic disease, however these mice exhibit expression of the mutant Kras, indicating that most likely endogenous IFN expression is sufficient to induce the cre transgene
• bone marrow cells from pIpC injected mice readily form colonies, predominately monocyte colony-forming units (M-CFUs) in a growth factor-independent manner unlike controls
• myeloproliferative phenotype
• myeloid hyperplasia of bone marrow
• erythroid expansion was seen in red pulp of spleen in 5 of 16 cases
• the liver shows perivascular and periportal infiltration by myeloid and erythroid cell populations
• expansion of red pulp in spleen by granulocyte/monocyte lineages in 11 out of 16 cases
• mice injected with pIpC become anemic
• mice injected with pIpC have a mean hematocrit of 27% compared with 45% in controls
• leukocytosis, usually involving increases in granulocytes, in both pIpC and non-pIpC treated mice
• leukocytosis in mice injected with pIpC is mainly due to an increase in granulocyte population
• mice injected with pIpC show expansion of the red pulp by varying degrees of granulocytic

immune system
• mice injected with pIpC develop moderate to severe splenomegaly
• 4-7 week old mice injected with pIpC develop a myeloproliferative disorder
• bone marrow of mice injected with pIpC shows myelomonocytic expansion
• all mice that are not treated with pIpC also develop a hematopoietic disease, however these mice exhibit expression of the mutant Kras, indicating that most likely endogenous IFN expression is sufficient to induce the cre transgene
• bone marrow cells from pIpC injected mice readily form colonies, predominately monocyte colony-forming units (M-CFUs) in a growth factor-independent manner unlike controls
• myeloproliferative phenotype
• myeloid hyperplasia of bone marrow
• leukocytosis, usually involving increases in granulocytes, in both pIpC and non-pIpC treated mice
• leukocytosis in mice injected with pIpC is mainly due to an increase in granulocyte population
• mice injected with pIpC show expansion of the red pulp by varying degrees of granulocytic
• 6 of 17 mice injected with pIpC develop nodal lymphoid hyperplasia

liver/biliary system
• perivascular and periportal infiltration in liver by myeloid and erythroid cells similar to what is seen in spleen

integument
• ruffled fur
• 12 of 19 mice injected with pIpC develop squamous papillomas involving the anal and vulvo-vaginal skin and 8 of 22 mice develop squamous papillomas involving the ear
• 2 of 6 non-pIpC treated mice show ear squamous papillomas

digestive/alimentary system
• 8 of 22 mice injected with pIpC develop squamous papillomas involving the esophageal mucosa
• 8 of 25 mice injected with pIpC develop squamous papillomas involving the oral mucosa
• 2 of 6 non-pIpC treated mice show oral squamous papillomas

endocrine/exocrine glands
• 7 of 25 mice injected with pIpC develop thymic T cell lymphoblastic lymphomas
• 2 of 6 non pIpC treated mice show thymic lymphomas

respiratory system
• 10 of 17 mice injected with pIpC exhibit multiple nodules in the lungs consisting of proliferating type II penumocytes
• 5 of 6 non pIpC treated mice show pulmonary adenomas

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
juvenile myelomonocytic leukemia DOID:0050458 OMIM:607785
J:88163


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
05/14/2024
MGI 6.23
The Jackson Laboratory